Aster DM Healthcare (ASTERDM) M&A Announcement summary

Deal rationale and strategic fit

• Merger creates one of the top three hospital chains in India, expanding to 38 hospitals and over 10,150 beds across 27 cities and nine states, with minimal overlap and strong presence in South and Central India.

• Diversified platform with four major brands and a holistic healthcare ecosystem spanning hospitals, clinics, labs, and pharmacies.

• Strategic alignment leverages Aster's expertise and Quality Care's strong network, enhancing healthcare accessibility and standards.

• Backed by Blackstone, providing global expertise and financial strength.

• Focus on both brownfield and greenfield expansion to reach 13,300 beds by FY 2027.

Financial terms and conditions

• QCIL valued at 25.2x FY24 EV/EBITDA; Aster at 36.6x FY24 EV/EBITDA, a 45% premium for Aster.

• Merger is cash-neutral and expected to be EPS-accretive from the first full year.

• Aster will acquire a 5% stake in QCIL pre-merger via share issuance; remaining shares swapped at agreed ratio.

• Post-merger, Aster shareholders will hold 57.3%, QCIL shareholders 42.7%; Aster Promoters and Blackstone will hold 24% and 30.7% respectively.

• Share count to expand from 50 crore to 87.16 crore shares post-merger.

Synergies and expected cost savings

• Anticipated EBITDA upside of 10-15% from near-term synergies, including revenue growth, supply chain efficiencies, integrated doctor model, and lower overheads.

• Margin profile to improve, targeting 24-25% EBITDA margin within three to four years.

• Enhanced ability to attract and retain medical talent and optimize procurement and operations.

• Brownfield expansions and cross-leveraging of clinical strengths to drive further margin growth.